MedTrace Logo

A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV

NCT01809223 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2014-06-04

No results posted yet for this study

Summary

This study is design to evaluate the effect of conbercept therapy on visual acuity and anatomic outcomes compared to sham injection and durability of response observed in subjects with choroid neovascularization secondary to pathological myopia.

Conditions

  • Choroid Neovascularization Secondary to Degenerative Myopia

Interventions

DRUG

conbercept, Fixed

intravitreal injection of 0.5 mg conbercept per month, fixed injection

DRUG

conbercept, PRN

intravitreal injection of 0.5 mg conbercept as need, PRN

OTHER

sham injection

sham intravitreal injection per month, fixed injection

Sponsors & Collaborators

  • Chengdu Kanghong Biotech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2014-02-28
Completion
2015-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01809223 on ClinicalTrials.gov